MA39495A - Formulations d'aripiprazole présentant des vitesses d'injection plus élevées - Google Patents

Formulations d'aripiprazole présentant des vitesses d'injection plus élevées

Info

Publication number
MA39495A
MA39495A MA039495A MA39495A MA39495A MA 39495 A MA39495 A MA 39495A MA 039495 A MA039495 A MA 039495A MA 39495 A MA39495 A MA 39495A MA 39495 A MA39495 A MA 39495A
Authority
MA
Morocco
Prior art keywords
ariipiprazole
formulations
injection rates
higher injection
rates
Prior art date
Application number
MA039495A
Other languages
English (en)
Inventor
Migali B Hickey
Jennifer Vandiver
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of MA39495A publication Critical patent/MA39495A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA039495A 2014-03-20 2015-03-19 Formulations d'aripiprazole présentant des vitesses d'injection plus élevées MA39495A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461955976P 2014-03-20 2014-03-20

Publications (1)

Publication Number Publication Date
MA39495A true MA39495A (fr) 2015-09-24

Family

ID=54141031

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039495A MA39495A (fr) 2014-03-20 2015-03-19 Formulations d'aripiprazole présentant des vitesses d'injection plus élevées

Country Status (12)

Country Link
US (8) US9452131B2 (fr)
EP (1) EP3119399A4 (fr)
JP (2) JP6524110B2 (fr)
CN (2) CN110368360A (fr)
AU (2) AU2015231278B2 (fr)
BR (1) BR112016021535A8 (fr)
CA (1) CA2943213C (fr)
IL (2) IL247517B (fr)
MA (1) MA39495A (fr)
MX (2) MX376057B (fr)
RU (1) RU2688233C2 (fr)
WO (1) WO2015143145A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010266018B2 (en) 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
MX358344B (es) 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
EP2827868B8 (fr) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters d'acides gras
WO2014080285A2 (fr) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Compositions pharmaceutiques ayant une plus grande stabilité au stockage
CN110368360A (zh) * 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
EP3658540B1 (fr) * 2017-07-28 2021-12-01 Interquim, S.A. Procédé de préparation du lauroxil d'aripiprazole
CN110204488A (zh) * 2018-02-28 2019-09-06 四川科伦药物研究院有限公司 一种月桂酰阿立哌唑的制备方法
WO2019173230A1 (fr) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Stratégie de dosage d'aripiprazole
US20210290609A1 (en) * 2018-12-04 2021-09-23 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
US12312315B2 (en) * 2019-07-12 2025-05-27 Interquim, S.A. Process for the preparation of aripiprazole lauroxil

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2418499A (en) 1944-06-20 1947-04-08 Du Pont 2-alkoxymethylmercapto-thiazoles and thiazolines and a process for preparing the same
GB849541A (en) 1956-02-23 1960-09-28 Rohm & Haas Preparation of unsaturated cyclic urea derivatives
DE1273533B (de) 1962-09-08 1968-07-25 Hoechst Ag Verfahren zur Herstellung von N-(ª‡-Alkoxy-alkyl)-carbonsaeureamiden
NL128370C (fr) 1964-08-28
US3523121A (en) 1967-03-09 1970-08-04 Rohm & Haas Certain 2-carbamoyl-3-isothiazolenes
US3573308A (en) 1969-04-03 1971-03-30 Hoffmann La Roche 3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds
US3957808A (en) 1969-09-03 1976-05-18 Rohm And Haas Company 3-alkoxyisothiazoles
US4727151A (en) 1974-06-24 1988-02-23 Interx Research Corporation Labile quaternary ammonium salts as prodrugs
US3998815A (en) 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4204065A (en) 1975-09-22 1980-05-20 Interx Research Corporation Soft quaternary surface active agents and method of using same
JPS5331676A (en) 1976-09-06 1978-03-25 Mitsui Toatsu Chem Inc Uracil derivatives and their preparation
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
DE3149010A1 (de) 1981-12-10 1983-07-07 A. Nattermann & Cie GmbH, 5000 Köln (+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten
US4428935A (en) 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
IT1212743B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Sali quaternari di derivati di benzo[ 1,4 ]diazepinonici,pirido [1,4]benzodiazepinonici,prido [1,5]benzodiazepinonici e loro atti vita' farmacologica
JPS602331A (ja) 1983-06-20 1985-01-08 Yoshino Kogyosho Co Ltd 飽和ポリエステル樹脂製壜の成形方法
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
DK302883D0 (da) 1983-06-30 1983-06-30 Hans Bundgaard Allopurinol prodrugs
DE3544134A1 (de) 1984-12-15 1986-06-19 Mitsubishi Chemical Industries Ltd., Tokio/Tokyo Verfahren zur herstellung von n-((alpha)-alkoxyethyl) pyrrolidon
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1991000863A1 (fr) 1989-07-07 1991-01-24 Pfizer Inc. Agents antipsychotiques a base de piperazine d'heteroaryle
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
TW226016B (fr) 1991-12-30 1994-07-01 Sterling Winthrop Inc
US5462934A (en) 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU6156494A (en) 1993-03-08 1994-09-26 Eisai Co. Ltd. Phosphonic acid derivatives
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE4439493A1 (de) 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
JP3571795B2 (ja) 1995-04-18 2004-09-29 株式会社日本触媒 Ｎ−（１−アルキルオキシアルキル）カルバメート類の気相分子内脱アルコール反応用触媒およびｎ−ビニルカルバメート類の製造方法
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
UA48219C2 (uk) 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
DE19619819A1 (de) 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel
WO1998007414A1 (fr) 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprenant des microparticules de substances insolubles dans l'eau et procede de preparation associe
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
ID25533A (id) 1997-09-30 2000-10-12 Lilly Co Eli Formulasi 2-metil-tieno-benzodiazepin
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP2001527083A (ja) 1997-12-31 2001-12-25 ザ・ユニバーシティ・オブ・カンザス 第二級および第三級アミン含有薬剤の水溶性プロドラッグおよびその製造方法
CN1323295A (zh) 1998-08-26 2001-11-21 阿文蒂斯药物有限公司 调节细胞粘着抑制作用的氮杂双环化合物
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2311734C (fr) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Forme pharmaceutique orale a dissolution ultra-rapide
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6656505B2 (en) 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
ATE280164T1 (de) 2001-02-14 2004-11-15 Warner Lambert Co Benzothiadiazine als matrix metallproteinase inhibitoren
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
EP1383376A4 (fr) 2001-03-19 2006-03-08 Praecis Pharm Inc Formulations pharmaceutiques a liberation prolongee
EP1414798A2 (fr) 2001-04-03 2004-05-06 Aryx Therapeutics Opioides a action ultrabreve pour application transdermique
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2003068749A1 (fr) 2002-02-15 2003-08-21 Glaxo Group Limited Modulateurs des recepteurs vanilloides
AU2003257145B2 (en) 2002-08-02 2008-11-13 Merck Sharp & Dohme Corp. Substituted furo (2,3-b) pyridine derivatives
GEP20063996B (en) 2002-08-20 2006-12-11 Bristol Myers Squibb Co Aripiprazole complex formulation and use thereof
OA12923A (en) 2002-09-17 2006-10-13 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040161481A1 (en) 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
AU2003299691B2 (en) 2002-12-18 2008-06-05 Algorx Pharmaceuticals, Inc. Administration of capsaicinoids
DE10303669A1 (de) 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
US9125939B2 (en) 2003-05-23 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
HRP20080235T3 (hr) 2003-07-24 2008-07-31 Merial Limited Formulacija vakcine koja sadrži emulziju ulje-u-vodi
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200510721A (en) 2003-08-29 2005-03-16 Toshiba Kk Color reagent, concentration measuring kit, concentration measuring method and sensor chip for use therein
KR100931784B1 (ko) * 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
CA2551346A1 (fr) 2003-12-31 2005-07-21 Warner-Lambert Company Llc Derives de piperidine et de piperazine n-substitues
AU2005215257A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US7169803B2 (en) 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
US7119214B2 (en) 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
GB2413795A (en) 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
WO2006037090A2 (fr) 2004-09-28 2006-04-06 Purdue Research Foundation Promedicaments contenant des conjugues de phosphate-medicament et des analogues de ceux-ci
US7910577B2 (en) 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
WO2006090273A2 (fr) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones et composes relatifs a liants ceto ou hydroxyl destines au traitement de la schizophrenie
CN101198331B (zh) 2005-06-13 2012-05-02 大日本住友制药株式会社 增溶化制剂
EP1933814A2 (fr) 2005-09-15 2008-06-25 Elan Pharma International Limited Formulations aripiprazoliques nanoparticulaires
EP1777222A1 (fr) 2005-09-22 2007-04-25 Galantos Pharma GmbH Inhibiteurs de la cholinesterase avec une perméabilité améliorée de la barrière ématoencéphalique pour le traitement de troubles cognitifs
RU2008109958A (ru) 2005-10-31 2009-12-10 Пфайзер Продактс Инк. (Us) Кристаллические соли 7-[4-(4-нафталин-1-илпиперазин-1-ил)бутокси]-3, 4-дигидро-1н-[1, 8]нафтиридин-2-она
US20070185069A1 (en) 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
AU2007291234A1 (en) 2006-08-31 2008-03-06 Solvay Pharmaceuticals B.V. Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
US20090068290A1 (en) 2006-08-31 2009-03-12 Michel Bourin Bifeprunox doses for treating schizophrenia
CL2007002684A1 (es) 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
CA2671737A1 (fr) 2006-12-05 2008-06-12 Neurogesx, Inc. Promedicaments et procedes pour les fabriquer et les utiliser
WO2008076447A2 (fr) 2006-12-15 2008-06-26 Ordway Research Institute Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci
EP1961412A1 (fr) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Systèmes auto-microémulsifiants pour l'administration de médicaments
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP2134330B1 (fr) 2007-03-19 2013-05-08 Acadia Pharmaceuticals Inc. Combinaisons d'agonistes inverses ou antagonistes de 5-ht2a avec antipsychotiques
MY153868A (en) 2007-04-04 2015-03-30 Merck Sharp & Dohme Therapeutic agents
US20100292316A1 (en) 2007-07-18 2010-11-18 Research Development Foundation Improved therapeutic methods and compositions comprising chroman ring compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2076243B9 (fr) * 2007-08-27 2015-01-14 ratiopharm GmbH Formulation liquide du g-csf
WO2009052467A1 (fr) 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Procédés d'identification d'une résistance à l'inhibiteur de pi-3 kinase
WO2009060473A2 (fr) 2007-11-06 2009-05-14 Panacea Biotec Limited Compositions injectables, procédés et utilisations correspondantes
KR20100099292A (ko) 2007-12-19 2010-09-10 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
AU2009288200A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US8017515B2 (en) 2008-12-10 2011-09-13 Stats Chippac, Ltd. Semiconductor device and method of forming compliant polymer layer between UBM and conformal dielectric layer/RDL for stress relief
NZ594071A (en) 2009-01-26 2013-01-25 Egalet Ltd Controlled release formulations comprising morphine sulphate for continuous treatment of pain
TW201105667A (en) 2009-05-08 2011-02-16 Cytopathfinder Inc Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
AU2010266018B2 (en) 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
RU2543383C2 (ru) 2009-07-01 2015-02-27 Байер Матириальсайенс Аг Способ получения полиуретанового полимера, содержащего сложные полиэфирполиолы, имеющие концевые вторичные гидроксильные группы
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
CA2798172C (fr) 2010-01-07 2017-11-21 Alkermes Pharma Ireland Limited Promedicaments contenant des sels d'ammonium quaternaire
US20110166128A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
US20110166194A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Asenapine Prodrugs
JP6106437B2 (ja) 2010-01-07 2017-03-29 アルカーメス ファーマ アイルランド リミテッド 複素芳香族化合物のプロドラッグ
WO2011084850A1 (fr) 2010-01-07 2011-07-14 Alkermes, Inc. Promédicaments pour le traitement de la schizophrénie et des maladies bipolaires
EP2538202A4 (fr) 2010-02-16 2018-03-21 Hamamatsu Photonics K.K. Dispositif de calcul de concentration de gaz et module de mesure de concentration de gaz
WO2011140183A1 (fr) 2010-05-04 2011-11-10 Alkermes, Inc. Procédé de synthèse de lactames oxydés
CA2802733C (fr) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Promedicaments de composes nh-acides : derives esters, carbonates, carbamates et phosphonates
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
MX358344B (es) 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
NZ630428A (en) * 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) * 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
EP2827868B8 (fr) * 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters d'acides gras
WO2014080285A2 (fr) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Compositions pharmaceutiques ayant une plus grande stabilité au stockage
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂

Also Published As

Publication number Publication date
US11406632B2 (en) 2022-08-09
WO2015143145A1 (fr) 2015-09-24
US10085980B2 (en) 2018-10-02
MX376057B (es) 2025-03-07
US20230026422A1 (en) 2023-01-26
IL247517A0 (en) 2016-11-30
CA2943213C (fr) 2022-07-05
EP3119399A1 (fr) 2017-01-25
EP3119399A4 (fr) 2017-09-27
NZ762767A (en) 2023-09-29
RU2016141055A (ru) 2018-04-20
RU2688233C2 (ru) 2019-05-21
MX2016012041A (es) 2017-01-19
US9526726B2 (en) 2016-12-27
NZ723869A (en) 2020-09-25
CA2943213A1 (fr) 2015-09-24
US9452131B2 (en) 2016-09-27
US20200289504A1 (en) 2020-09-17
AU2015231278A1 (en) 2016-09-22
CN106132415A (zh) 2016-11-16
BR112016021535A2 (pt) 2017-08-15
US20180369239A1 (en) 2018-12-27
RU2016141055A3 (fr) 2018-11-02
CN110368360A (zh) 2019-10-25
US10238651B2 (en) 2019-03-26
JP2017507992A (ja) 2017-03-23
IL285227A (en) 2021-09-30
US11931355B2 (en) 2024-03-19
RU2019114425A (ru) 2019-07-30
US10813928B2 (en) 2020-10-27
US20250108047A1 (en) 2025-04-03
MX2020010839A (es) 2020-11-06
JP2019123749A (ja) 2019-07-25
IL247517B (en) 2021-09-30
AU2020202577A1 (en) 2020-05-07
JP6896015B2 (ja) 2021-06-30
US20170157117A1 (en) 2017-06-08
US20160263111A1 (en) 2016-09-15
AU2015231278B2 (en) 2020-01-23
JP6524110B2 (ja) 2019-06-05
AU2020202577B2 (en) 2022-07-07
US20190167673A1 (en) 2019-06-06
BR112016021535A8 (pt) 2021-07-20
US20150265529A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
MA39495A (fr) Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
PL3587417T3 (pl) Benzamidy podstawione 1,3-tiazol-2-ilem
IL251976A0 (en) Phage therapy
DK3171700T3 (da) Infusionsanlæg
EP3046853C0 (fr) Protecteur d'étagère
MA43873A (fr) Dspositif d'injection
PL3207149T3 (pl) Kompozycja farmaceutyczna o zwiększonej stabilności
UY4430S (es) “motocicleta”.
DK3134483T3 (da) Vandig sammensætning med forbedret brudforlængelse
UA30549S (uk) Логотип «дваждыдва»
UA30935S (uk) Логотип «inmag»
UA29959S (uk) Логотип «киарм»
UA30368S (uk) Логотип «аптека копійка»
UA28003S (uk) Логотип «wаlfіх»
UA29700S (uk) Пляшка «куманець»
ES1135060Y (es) " arado "
UA30401S (uk) Пляшка «триангулар»
UA32431S (uk) Стрем'янка
FR3027787B1 (fr) Seau'good
ITUB201551290U1 (it) Ovie' oviel
UA31292S (uk) Логотип «маланка»
UA31215S (uk) Каструля «іcook»
UA28620S (uk) Логотип «борщ»
UA32536S (uk) Логотип «нямушка»
UA28082S (uk) Логотип «iris»